Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells 4,500 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $6.93, for a total transaction of $31,185.00. Following the transaction, the director now owns 69,938 shares of the company’s stock, valued at approximately $484,670.34. The trade was a 6.05 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The stock was sold at an average price of $6.98, for a total transaction of $31,410.00.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded up $0.27 on Thursday, hitting $7.34. The company’s stock had a trading volume of 338,216 shares, compared to its average volume of 542,543. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a market capitalization of $446.64 million, a P/E ratio of -5.44 and a beta of 1.31. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a fifty day moving average price of $7.87 and a 200-day moving average price of $7.48.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter last year, the firm earned ($0.22) earnings per share. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts expect that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HCAT shares. Citigroup raised their price target on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Royal Bank of Canada increased their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Finally, Evercore ISI increased their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $11.79.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HCAT. Primecap Management Co. CA boosted its position in shares of Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after acquiring an additional 305,079 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in Health Catalyst during the third quarter worth approximately $897,000. Fred Alger Management LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at $6,858,000. Millrace Asset Group Inc. purchased a new stake in shares of Health Catalyst during the 3rd quarter valued at $1,568,000. Finally, Point72 Asset Management L.P. increased its holdings in shares of Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after buying an additional 211,805 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.